Ca-PRI Online Conference 2021

9-10 June 2021

Programme

Contents

Welcome!

Dear Ca-PRI 2021 delegate,

It gives us great pleasure to welcome you to the Ca-PRI 2021 online conference – the 13th Annual Meeting of the Cancer and Primary Care Research International network (Ca-PRI).

When the decision was made to cancel the Ca-PRI 2020 conference in Oxford last year due to the COVID-19 pandemic, few of us envisaged that we would still be unable to meet in person over a year later. What a challenging year it has been for many: our sympathy to any in the Ca-PRI community who have lost loved ones to COVID-19, or whose own health has been affected. We have all experienced restrictions and lockdowns; these have impacted patient care and health care delivery, as well as modified how we carry out many of our research activities.

The theme of Ca-PRI 2021 is 'Cancer and Primary Care: innovation and resilience in the era of COVID-19'. The programme includes research examining all aspects of the cancer pathway, including prevention, screening, diagnosis and management of survivors; there are also dedicated sessions focusing on covid-related research. Our Keynote speakers will challenge us to think more widely about our discipline (globally, and using AI); a Plenary session will present the Cancer Research UK Roadmap on Early Detection and Diagnosis of Cancer, with an associated Panel discussion of funding opportunities.

Over the years, Ca-PRI meetings have provided a great opportunity to catch up face to face, discuss research ideas and make new friends and colleagues at our various conference/ social events. Although we are on-line this time, we'll re-launch our face-to-face meetings in Oxford in 2022. In the meantime, please do join our timetabled Mixer sessions, and make use of the virtual SpatialChat platform that is available throughout the conference (details below).

We look forward to meeting you online over the coming days.

Dr Christine Campbell
Scientific lead, Ca-PRI 2021

Professor David Weller
Chair, Ca-PRI Executive Committee

On behalf of the Ca-PRI Executive Committee

Information and acknowledgements

Ca-PRI Twitter

Our Twitter handle is @caprinetwork.

Please use the hashtag **#CaPRI2021** when tweeting about this year's conference.

Ca-PRI website

A reminder that information about Ca-PRI can be found at our website:

https://www.ed.ac.uk/usher/cancer-primary-care-research-international-network

Zoom

The conference will be held on Zoom meeting. If you need to, please create a zoom account in advance of the conference via https://www.zoom.us/

Zoom Meeting Joining Link:

Wednesday 9 June

https://ed-ac-uk.zoom.us/j/84616363852
Meeting ID: 846 1636 3852
Passcode: Ca-Pri2021

Thursday 10 June

https://ed-ac-uk.zoom.us/j/88595226738
Meeting ID: 885 9522 6738
Passcode: Ca-Pri2021

Housekeeping rules

When joining the conference, you will be muted by default. You can unmute yourself by clicking Unmute in the bottom left corner of your Zoom window.

You can also choose to Stop Video if you prefer.

Click the Participants icon to access quick reactions at the bottom of the right-side panel.

Use the Chat function to submit your questions to the Chair who will put a selection of questions to the Presenter at the Q&A part of the session. Chat logs are visible to the Ca-PRI 2021 conference team.

The sessions will be recorded/pre-recorded in order to provide "catch up" opportunity. You will get an audio prompt as well as the visual notification on your screen when recording begins. If you prefer not to be captured in this recording, you can opt out by turning off your camera and microphone.

During the parallel sessions you will automatically be moved from the main room into your selected parallel session.

Access to Ca-PRI 2021 online conference recordings

A dedicated conference site, located on Sharepoint, has been created for you to view the following:

- Keynote presentations
- Plenary presentations
- Parallel oral presentations
- Parallel lightning presentations
- Poster presentations

You will receive an email, to the email address you registered to attend Ca-PRI 2021, inviting you to join Ca-PRI 2021 Online conference. You will be asked to create a Microsoft account/office 365 account if you don't have one already. Please check your "junk/spam" folder in case the email ends up in there, the email will be sent from Lorna Heaney.

All of the poster presentations are available from you to view.

Following the conference, all of the other presentations will be uploaded to view at a time suitable to yourself.

Ca-PRI 2021 Conference chat platform

We know that by using zoom we are unable to recreate the informal chats and networking that often takes place during coffee break and lunch when attending an in-person conference.

We would like to introduce you to https://spatial.chat/ where we have created a virtual space for you to catch up with colleagues during the conference.

Please click via the link below and create an account and you are then ready to interact!

https://spatial.chat/s/Ca-pri2021conference

1. Ensure your microphone and camera have been activated.

2. Click Join Space.

3. There are 3 virtual spaces dedicated to Ca-PRI 2021.

4. Panel on right hand side will show list of attendees who are in the conference space.

5. You will appear as a coloured dot with your initials/photo.

6. You can edit your profile to add your name and a brief description, as well as upload a photo of yourself in your profile.

7. As you move your dot around the space, and get closer to another coloured dot, you can then have a conversation.

8. If you move your dot away, you will leave a conversation.

9. We recommend you log-off from Spatial Chat during the dedicated conference sessions that take place on Zoom.

10. Our dedicated conference space will be open for the duration of the conference.

Programme: 9 & 10 June

Wednesday 9 June	
13.00	**Welcome, and housekeeping** Professor David Weller and Dr Christine Campbell
13.10	**Keynote** Dr Satish Gopal, Center for Global Health, National Cancer Institute "Looking ahead in global cancer research and control" Chairs: Dr Christine Campbell and Dr Rosalind Adam
13.40	**Oral parallel sessions** • Diagnosis in Primary Care – Chair: Professor Fiona Walter • Recognition and referral – Chair: Professor Henk van Weert • Treatment and Survivorship – Chair: Dr Annette Berendsen
14.40	**Break**
15.00	**Plenary session** Dr David Crosby, Cancer Research UK "Early Detection and Diagnosis of Cancer Roadmap" Panel discussion on international funding opportunities Dr Alexis Webb, Cancer Research UK, and Dr Gila Neta, National Cancer Institute, USA Chairs: Professor David Weller and Professor Larissa Nekhlyudov
15.40	**Lightning parallel sessions** • Screening and Survivorship – Chair: Dr Christine Campbell • COVID-19 – Chair: Professor Li Li • Early Diagnosis – Chair: Dr Rosalind Adam
16.20	**Brief break** - please don't log off
16.30	**Mixer breakout rooms**
16.55	**Wrap up and close**

Thursday 10 June	
9.00	**Welcome, and housekeeping** Dr Christine Campbell and Professor David Weller
09.10	**Keynote** Professor Mihaela van der Schaar, University of Cambridge "Utilising the power of AI to promote earlier detection of cancer in primary care" Chairs: Professor Henk van Weert and Dr Charles Helsper
09.40	**Oral parallel sessions** • Screening and Detection – Chair: Dr Christine Campbell • Routes and Referrals – Chair: Dr Brian Nicholson • Treatment and Survivorship – Chair: Dr Rosalind Adam
10.40	**Break**
11.00	**COVID-19 Plenary Oral session** – Chair: Professor Jon Emery
11.40	**Lightning talks** • Awareness, Screening and Detection – Chair: Dr Charles Helsper • Survivorship and Patient support – Chair: Dr Annette Berendsen • Early Diagnosis – Chair: Professor Jon Emery
12.20	**Brief break** - please don't log off
12.30	**Mixer breakout rooms**
12.50	**Wrap up (Oxford 2022 presentation), and close** Professor David Weller

POSTERS – available online throughout the conference

Diagnosis in Primary Care	Recognition and Referral	Treatment and Survivorship
Chair: Professor Fiona Walter	Chair: Professor Henk van Weert	Chair: Dr Annette Berendsen
O01 Help-seeking experiences in primary care for symptoms related to colorectal cancer during COVID-19 **Katriina Whitaker & Athena Ip**, *University of Surrey, UK*	**O05** Using action planning to explore acceptable interventions to improve the recognition and referral of cancer in primary care: an exploratory study **Daniel Jones**, *University of Leeds, UK*	**O09** Coordination between specialized cancer care teams and non-profit community organizations: a multiteam system perspective **Dominique Tremblay**, *Université de Sherbrooke, Canada*
O02 Missing cancer patients in the Covid era **Diane Primrose**, *Centre for Sustainable Delivery - Golden Jubilee National Hospital, UK*	**O06** Guideline discordant diagnostic care: when do primary care referrals not reflect guidelines for suspected cancer? **Gary Abel**, *University of Exeter, UK*	**O10** Home-based Physical Activity to Alleviate Fatigue in Cancer Survivors: A Systematic Review and Meta-analysis **Famke Huizinga**, *University Medical Center Groningen, Department of General Practice and Elderly Care Medicine, The Netherlands*
O03 Cancer detection via primary care urgent referral in England 2009/10-2018/19 and the association with practice characteristics **Thomas Round**, *King's College London, UK*	**O07** Could ovarian cancer diagnostic prediction models improve the triage of symptomatic women in primary care? **Garth Funston**, *Department of Public Health and Primary Care, University of Cambridge, UK*	**O11** Receipt of active surveillance care for men with favorable-risk prostate cancer: can we leverage primary care? **Archana Radhakrishnan**, *University of Michigan, USA*
O04 Morbidity and measures of the diagnostic process in primary care among patients subsequently diagnosed with cancer **Monica Koo**, *University College London, UK*	**O08** Missed/delayed referrals for investigation of suspected cancer: a candidate indicator of practice-level care quality **Luke Mounce**, *University of Exeter, UK*	**O12** Specialist versus primary care prostate cancer follow-up: a process evaluation of a randomized controlled trial **Barbara Wollersheim**, *Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Netherlands*

Lightning talks: Wednesday 9 June, 15.40–16.20

Screening & survivorship	COVID-19	Early Diagnosis
Chair: Dr Christine Campbell	Chair: Professor Li Li	Chair: Dr Rosalind Adam
L01 Using co-design to develop the roll out of a lung cancer screening programme: Barriers and facilitators in primary care **Lynsey Brown**, *School of Medicine, University of St Andrews, UK*	**L09** Cancer and Primary Care in Denmark: Monitored Effects of COVID-19 **Soren Worsoe Laursen**, *The Danish Cancer Society, Denmark*	**L17** Time from presentation to pre-diagnostic chest X-ray among symptomatic lung cancer patients in England **Kirsten Arendse**, *Médecins Sans Frontières, South Africa, Belgium Trust, Belgium*
L02 First 5 years of a lung cancer screening program in a US healthcare system: Lung Cancer Screening Optimization in the US (LOTUS) **Robert Greenlee**, *Marshfield Clinic Research Institute, USA*	**L10** Impact of COVID-19 on cancer screening services and the role of multi-cancer early detection (MCED) testing **Velicia Bachtiar**, *Grail Bio UK Ltd, UK*	**L18** Smoking status and barriers for healthcare seeking with lung cancer symptoms –a population-based study **Lisa Maria Sele Sætre**, *Research Unit for General Practice, Institute of Public Health, University of Southern Denmark, Denmark*
L03 Scoping literature review: Identifying target groupsfor lung cancer screening –the potential and limitations of primary care data **Debbie Cavers**, *University of Edinburgh, UK*	**L11** The impact of remote consultation on GPs delivery of cancer prevention advice and support during the Covid-19 pandemic. **Lindsay MacDonald,** *Cancer Research UK, UK*	**L19** Cancer incidence after guideline discordant GP referral behaviour for potential cancer features. **Bianca Wiering,** *University of Exeter, UK*
L04 Awareness and support of HPV testing and patient self-collection for cervical cancer screening among primary care clinicians **Kathy McLaughlin**, *Mayo Clinic Department of Family Medicine and Robert D and Patricia E. Kern Center for the Science of Health Care Delivery, USA*	**L12** GP use of Chest x-ray for patients with suspected lung cancer and perception of factors contributing to diagnostic delays. **Lindsay MacDonald**, *Cancer Research UK, UK*	**L20** How do and how can GP waiting rooms best raise awareness of the signs and symptoms of different cancers? Patient survey results **Laurie Dunn**, *Hull York Medical School, UK*
L05 "Bridging the Gap" between Oncology and Primary Care for Underserved Complex Cancer Survivors –Project CONNECT **Bijal Balasubramanian**, *University of Texas Health Science Center at Houston -School of Public Health, USA*	**L13** Assessing patient-reported impact of COVID-19 among cancer survivors in a primary-care centered survivorship clinic **Aamna Kabani**, *Johns Hopkins University School of Medicine, Baltimore, MD, USA*	**L21** Cancer Diagnosis in the Time of Covid-19: A Qualitative study of GPs' experiences during the Covid-19 pandemic **Claire Friedemann Smith**, *University of Oxford, UK*

Lightning talks: Wednesday 9 June, 15.40–16.20

Screening & survivorship	COVID-19	Early Diagnosis
Chair: Dr Christine Campbell	Chair: Professor Li Li	Chair: Dr Rosalind Adam
L06 Implementation study of an online communication system in St. John's, Canada: eOncoNote challenges and lessons learned **Bojana Petrovic**, *Department of Family & Community Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto, Canada*	**L14** Addressing problem-related distress among cancer survivors during COVID-19: findings from the Johns Hopkins Primary Care for Cancer Survivors (PCCS) Clinic **Aamna Kabani**, *Johns Hopkins University School of Medicine, Baltimore, MD, USA*	**L22** The risk of gastrointestinal cancers in patients with new unexplained abdominal pain and concurrent weight loss in primary care **Niamh Gibson**, *University of Exeter, UK*
L07 Impact of Race and Ethnicity on Metabolic Syndrome Treatment Prevalence among U.S. Colorectal Cancer Survivors **Denalee O'Malley**, *Rutgers-RWJMS, USA*	**L15** Innovations during the Covid-19 Pandemic **Saloni Jain,** *Macmillan GP Facilitator, Hywel Da University Health Board, UK*	**L23** A systematic review investigating the role of GP factors on decisions to investigate symptoms of possible cancer **Victoria Hardy**, *University of Cambridge, UK*
L08 First results of the BLANKET-trial: treating fear of cancer recurrence in primary care **Yvonne Luigjes**, *Helen Dowling Institute and University Medical Center Utrecht, Netherlands*	**L16** Covid 19: Impact on delivering Cancer Education in Primary care **Saloni Jain,** *Macmillan GP facilitator, Hywel Da University Health Board, UK*	**L24** Validation and Public Health Modelling of Risk Prediction Models for Kidney Cancer using UK Biobank **Hannah Harrison**, *Department of Public Health and Primary Care, University of Cambridge, UK*

Screening and Detection	Routes and Referrals	Treatment and Survivorship
Chair: Dr Christine Campbell	Chair: Dr Brian Nicholson	Chair: Dr Rosalind Adam
O13 Novel biomarkers ready for evaluation in low-prevalence populations for the early detection of lower GI cancers *Paige Druce, The University of Melbourne, Australia*	**O17** Routes to diagnosis and the association with the prognosis in patients with cancer in Denmark *Henry Jensen, Research Unit for General Practice, Aarhus, Denmark*	**O21** Cancer in Primary Care Research Priorities in Australia *Kristi Milley, Centre for Cancer Research, Department of General Practice, University of Melbourne, Australia*
O14 The costs and benefits of riskstratification for colorectal cancer screening based on phenotypic and genetic risk *Juliet Usher-Smith, University of Cambridge, UK*	**O18** Exploring complexity in international primary care referral pathways for the management of suspected cancer *Charlotte Lynch, Cancer Research UK*	**O22** Impact of multimorbidity clusters on primary care and hospital use among long-term breast cancer survivors: results from the SUR *Anna Jansana, Department of Epidemiology and Evaluation, Hospital del Mar Institute for Medical Research, Barcelona, Spain*
O15 Lung cancer screening risk score in Primary Care *Bhautesh Jani, University of Glasgow, UK*	**O19** Perspectives on referrals for suspected cancer: A qualitative study with patient's and healthcare workers *Thomas Round, King's College London, UK*	**O23** Fatigue among Long-Term Breast Cancer Survivors: A Controlled Cross-Sectional Study *Saskia Maass, Department of General Practice and Elderly Care Medicine, University Medical Center Groningen, University of Groningen, Netherlands*
O16 Performance of screening tests for Oesophageal Squamous Cell Carcinoma: a systematic review and meta-analysis *Martin Wong, The Chinese University of Hong Kong, Hong Kong*	**O20** Exploring ethnic differences in the routes to diagnosis of common cancers: a retrospective cohort study using Clinical Practice *Tanimola Martins, University of Exeter, UK*	**O24** Risk prediction models for recurrence and survival after treatment of localised kidney cancer: a systematic review *Lanxin Li and Lydia Roberts, University of Cambridge, Cambridge, UK*

Lightning talks: Thursday 10 June, 11.40–12.20

Awareness, Screening and Detection	Survivorship and Patient support	Early Diagnosis
Chair: Dr Charles Helsper	Chair: Dr Annette Berendsen	Chair: Professor Jon Emery
L25 Process Evaluation of the ABACus3 trial: a targeted cancer awareness intervention for adults living in deprived areas of the UK *Harriet Quinn-Scoggins, Cardiff University, UK*	**L34** Healthcare practices that increase quality of care in cancer trajectories from a general practice perspective: A scoping review *Gitte Bruun Lauridsen, Research Unit for General Practice, Department of Public Health, University of Southern Denmark, Denmark*	**L43** Symptom perceptions and help-seeking behaviours of Omani patients diagnosed with late-stage colorectal cancer: A qualitative study *Mahera AL-Suqri, Department of Psychiatry, Samail Hospital, Ministry of Health, Oman*
L26 A bibliometric analysis of cancer in primary care research 2013-2019 *Mairead McNamara, Centre for Cancer Research, Department of General Practice, University of Melbourne, Australia, 3000, Australia*	**L35** A meta-ethnography of cultural influences on cancer-related psychological interventions *Dipesh Gopal, Queen Mary, University of London, UK*	**L44** Healthcare workers perspectives on potential delays in cancer diagnosis: A systematic review of qualitative research *Elise Crayton, University College London, Centre for Behaviour Change, UK*
L27 Reworking routines in primary healthcare: Adapting standarized cancer patient pathways while continuing practice *Petter Fjällström, Department of Nursing, Umeå University, Sweden*	**L36** General practitioner - versus surgeon-led colon cancer survivorship care, with or without access to an eHealth application *Julien Vos, Amsterdam UMC, location AMC, the Netherlands*	**L45** Can artificial intelligence/machine learning (AI/ML) aid the early detection of skin cancer in primary care settings? *Owain Jones, University of Cambridge, UK*
L28 Risk of cancer and other serious diseases among patients with unexpected weight loss: a large matched cohort analysis *Diana Withrow, Nuffield Department of Primary Care, University of Oxford, UK*	**L37** Ecological Momentary Assessment for the early detection of depression in survivors of cancer in primary care *Jolien Alissa Panjer, University of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine, Netherlands*	**L46** Future Health Today: Development of an evidence-based support tool to increase follow-up in people at risk of undiagnosed cancer *Javiera Martínez- Gutiérrez, Department of General Practice, University of Melbourne, Australia; Pontificia Universidad Catolica de Chile, Santiago, Chile*
L29 Should we provide advice about prevention and early detection of other cancers as part of the breast cancer screening programme? *Suzanne Scott, King's College London, UK*	**L38** Evaluating an interactive acceptance and commitment therapy (ACT) workshop for trained therapists working with cancer patients *Elisavet Moschopoulou, Queen Mary University of London, UK*	**L47** Guideline-concordant chest X-ray imaging for suspected cancer among individuals with dyspnoea or haemoptysis *Monica Koo, University College London, UK*

Awareness, Screening and Detection	Survivorship and Patient support	Early Diagnosis
Chair: Dr Charles Helsper	Chair: Dr Annette Berendsen	Chair: Professor Jon Emery
L30 Exploring the social and ethical implications of risk stratified screening for society – a community jury study ***Rebecca Dennison**, University of Cambridge, UK*	**L39** Feasibility of seamless care transitions using structured active handovers from oncology nurse navigators in secondary care to district nurses in primary care ***Claire Micaux**, Karolinska institutet; Health Care Services Stockholm County, Sweden*	**L48** Targeted encouragement of GP consultations for possible cancer symptoms: randomised controlled trial ***Jean-Pierre Laake**, University of Warwick, Warwick Medical School. 2. Queen Mary University of London, Centre for Cancer Prevention, UK*
L31 Development and user-testing of a brief decision aid for low-dose aspirin use as a preventive approach alongside screening for ccolorectal cancer to an age eligible screening population in Wales (UK) ***Lenira Ferreira Semedo**, Cardiff University, UK*	**L40** Substitution of follow-up for patients with breast and colorectal cancer: views of general practitioners ***Geertje Liemburg**, University of Groningen, University Medical Center Groningen, department of General Practice, Groningen, The Netherlands*	**L49** Variation in the use of blood tests in primary care among patients subsequently diagnosed with cancer ***Ben Cranfield**, University College London, UK*
L32 A systematic review of effectiveness, and factors affecting implementation, of Community-Based Resources to increase cervical cancer screening in sub-Saharan Africa ***Danladi Adamu**, Usher Institute, University of Edinburgh, UK; College of Medical Sciences, Gombe State University, Gombe, Nigeria*	**L41** End-of-life cancer care provision in NSW Australia, does geographic variation play a role? ***Jessica Cerni**, The University of Wollongong, Australia*	**L50** Interventions for improving early diagnosis of lung cancer – a community partnership approach ***Ross Lawrenson**, Medical Research Centre, Te Huataki Waiora, School of Health, The University of Waikato, New Zealand*
L33 Cervical and bowel cancer screening intentions during the Covid-19 pandemic: a mixed-methods study ***Yvonne Moriarty**, Centre for Trials Research, Cardiff University, UK*	**L42** Treatment goals and changes over time in older patients with non-curable cancer ***Mariken Stegmann**, University of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine, Netherlands*	**L51** Informed choice and attitudes regarding a genomic test to predict risk of colorectal cancer in general practice ***Sibel Saya**, The University of Melbourne, Australia*

COVID-19 Plenary session

Chair: Professor Jon Emery

O25

What is the impact of COVID-19 on cancer symptom experience and help-seeking behaviour in the United Kingdom?

Harriet Quinn-Scoggins & Rebecca Cannings-John, Cardiff University, UK

O26

The impact of the COVID pandemic on presentations to general practice with cancer-related symptoms in the Netherlands

Matthew Grant, Department of Cancer Epidemiology, Julius Centre, UMC Utrecht, The Netherlands

O27

Impact of the COVID-19 pandemic on the clinical assessment of possible cancer in primary care: a qualitative study of GP views

Natalia Calanzani, The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

Posters

Poster room 1 – Cross-cutting

Title	Presenter
P01 Primary Care's Contributions to Cancer Care Continuum Research and Innovation: Are We Keeping up with Population Trends?	*Youngjee Choi*, *John Hopkins University School of Medicine, USA*
P02 Attitudes Towards Cancer and Cancer Patients: A Cross-Sectional Study of Omani Public Attending Teaching Hospital	*Mohammed Al-Azri*, *Sultan Qaboos University, Department of Family Medicine and Public Health, College of Medicine and Health Sciences, Oman*
P03 Global Incidence and Mortality of Thyroid Cancer: a trend analysis	*Junjie Huang*, *The Chinese University of Hong Kong*
P04 A questionnaire study of rural and urban patients' requirements and experiences of Out-of-hours medical services	*Wei Lynn Khor*, *Centre of Academic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, UK*
P05 GP and cancer patient perceptions/experiences of remote consultations	*Charlotte Ide-Walters*, *Cancer Research UK, UK*

Poster room 2 – Primary Prevention, Screening, and the interface with Early Diagnosis

Title	Presenter
P06 A RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases	*Shakria Milton,* *The University of Melbourne, Australia*
P07 Primary care-based educational interventions to reduce morbidity and mortality from lung cancer and other respiratory illnesses in rural India	*Biswajit Paul*, *Christian Medical College, Tamil Nadu, India*
P08 Knowledge of symptoms, time to presentation and barriers to medical help-seeking among Omani women diagnosed with breast cancer	*Mohammed Al-Azri*, *Sultan Qaboos University, Department of Family Medicine and Public Health, College of Medicine and Health Sciences, Oman*
P09 A mixed methods study exploring symptom appraisal and help seeking in Australian upper gastrointestinal cancer patients	*Napin Karnchanachari*, *Department of General Practice, University of Melbourne, Melbourne, Australia*
P10 Reasons for intending to accept or decline kidney cancer screening: thematic analysis of free text from an online survey	*Charlotte Freer-Smith*, *University of Cambridge School of Clinical Medicine, UK*
P11 Perspectives of family physicians towards access to lung cancer screening for individuals living with low income	*Ambreen Sayani*, *Women's College Hospital, Canada*
P12 An Audit to assess whether Faecal Immunochemical Tests were carried out with referrals on the colorectal cancer pathway in a Suffolk Primary Care Practice during COVID-19 pandemic	*Megha Anil*, *University of Cambridge, UK*
P13 Knowledge, attitudes and practices around cervical cancer screening amongst under- or never-screened women offered Pap tests	*Kimberly Devotta*, *St. Michael's Hospital, Toronto Canada*
P14 Factors associated with participation in lung cancer screening among Chinese smokers: a population-based study	*Junjie Huang*, *The Chinese University of Hong Kong, Hong Kong*
P15 COVID-19 and cancer screening in Scotland: a national and coordinated approach to minimising harm	*Christine Campbell*, *The University of Edinburgh, UK*
P16 Assessment of women's experiences of thermal ablation treatment within a cervical cancer 'screen and treat' service in Malawi	*Christine Campbell*, *The University of Edinburgh, UK*

Poster room 3 – Early Diagnosis

Title	Presenter
P17 An Audit to assess whether appropriate information was obtained and given for 2 week wait cancer referrals in a Suffolk Primary	*Natasha Thomas, University of Cambridge, UK*
P18 Forming Scotland's first Early Cancer Diagnostic Centres	*Diane Primrose, Centre for Sustainable Delivery, Golden Jubilee National Hospital, UK*
P19 Finding Lung Cancer Early	*Diane Primrose, Centre for Sustainable Delivery - Golden Jubilee National Hospital, UK*
P20 FIT for symptomatic patients; UK GPs access, use and knowledge	*Lindsay MacDonald, Cancer Research UK, UK*
P21 Are mental health conditions associated with an increased risk of emergency colorectal cancer diagnosis?	*Cristina Renzi, University College London, UK*
P22 Patient willingness to visit primary and secondary care during COVID-19	*Charlotte Ide-Walters, Cancer Research UK, UK*
P23 What causes delayed lung cancer diagnosis of patients who have never smoked? A rapid review	*Sandra van Os, Department of Applied Health Research, University College London, UK*
P24 How do and how can GP waiting rooms best raise awareness of the signs and symptoms of different cancers? A staff interview study	*Laurie Dunn, Hull York Medical School, UK*
P25 The GLANCE study: Exploring the role, use, and utility of General Practitioners' gut feelings for cancer and serious disease	*Claire Friedemann Smith, University of Oxford, UK*
P26 Healthcare Use by Men with Urinary Symptoms (HUMUS)	*Tanimola Martins, University of Exeter, UK*
P27 Systematic review of methodological approaches in the use of time intervals in research and dose-response meta-analysis	*Allison Drosdowsky, Department of General Practice and Centre for Cancer Research, University of Melbourne, Australia*
P28 ThinkCancer!: Feasibility of a behaviour change intervention for early cancer diagnosis and safety netting in primary care	*Jessica Roberts, Bangor University, UK*
P29 General practitioner use of a faecal immunochemical test for patients with low-risk symptoms of bowel cancer in England	*Natalia Calanzani, The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK*
P30 Help-Seeking for symptoms of colorectal cancer among people in rural Yorkshire	*Christina Dobson, Newcastle University, UK*

Posters

Poster room 4 – Treatment and Survivorship

Title	Presenter
P31 How do patients with advanced cancer (and close persons) experience continuity in primary palliative care? A mixed-methods review	*Emilie Couchman, University of Sheffield, UK*
P32 Understanding Needs of Cancer Survivors and Caregivers: Perspectives for Intervention Development from a Cancer Center in Southern India	*Sudha Sivaran, Center for Global Health, US National Cancer Institute, US National Institutes of Health, USA*
P33 Identifying and Describing Cancer Survivors: Implications for Cancer Survivorship Research and Clinical Care	*Michelle Doose, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA*
P34 A multi-centre RCT comparing Acceptance and Commitment Therapy (plus) and usual care versus usual aftercare only: SURECAN Trial	*Imran Khan, Queen Mary, University of London, UK*
P35 Perspectives of Adolescent and Young Adult Cancer Survivors: Review of Community-Based Discussion Boards	*Alexandra Smith, Frank H. Netter MD School of Medicine, Quinnipiac University, USA*
P36 Perspectives and experiences of Canadian physiotherapists related to working with people diagnosed with advanced cancer: a mixed-methods study	*Shirin Shallwani, University of Ottawa School of Rehabilitation Sciences, Ottawa, Ontario, Canada*
P37 Primary care use after cancer treatment: findings from a population-based study in Nova Scotia, Canada	*Robin Urquhart, Dalhousie University, Canada*
P38 Living with and beyond cancer with comorbid illness: qualitative insights to patient and carer experiences	*Debbie Cavers, University of Edinburgh, UK*
P39 Feasibility of seamless care transitions using structured active handovers	*Claire Micaux, Karolinska Institutet, Health Care Services Stockholm County, Sweden*
P40 Patients' perspectives on a talking therapy for cancer aftercare	*Sheila Donovan, Queen Mary, University of London, UK*
P41 How well do healthcare professionals know of the priorities of their older patients regarding treatment outcomes?	*Daan Brandenbarg, University of Groningen, University Medical Center Groningen, Department of General Practice and Elderly Care Medicine, Netherlands*

Dr Satish Gopal
Center for Global Health at the National Cancer Institute

Biography

Satish Gopal, M.D., M.P.H. was appointed Director of the Center for Global Health (CGH) at the National Cancer Institute (NCI) in February 2020. In this role, he oversees the development of initiatives and collaborations with other NCI divisions, NCI-Designated Cancer Centers, and countries to support cancer research and cancer research networks, promote cancer control planning, and build capacity in low- and middle-income countries. Previously, Dr Gopal has provided leadership and expertise on NIH working groups, and review committees and boards. In 2018 he was selected to advise the NCI Director on the NCI global portfolio as Co-Chair of the NCI Advisory Board Ad Hoc Global Health Working Group. Before coming to NCI, Dr Gopal was the Cancer Program Director for the University of North Carolina (UNC) Project-Malawi, in collaboration with the Malawi Ministry of Health.

Abstract

Satish will discuss global cancer research and control from the perspective of the NCI Center for Global Health, in the context of the ongoing global pandemic and with a particular focus on low- and middle-income countries. He will describe how the cancer research and control community can help address global cancer burden, realize important scientific opportunities, and promote research and health equity.

Dr David Crosby
CRUK

Biography

David Crosby is head of prevention and early detection research at Cancer Research UK (CRUK), a fundraising research charity and the world's second largest non-commercial funder of cancer research, after the US government.

David began life as a baby, before becoming a pharmacologist, completing a PhD studying cell signalling in platelets. He spent time in academia, lecturing in clinical pharmacology. He moved into industry, identifying and evaluating new clinical development opportunities for Linde Gas Therapeutics, the world's largest medical gases company. He then moved into the public sector, joining the UK government research funding agency, the Medical Research Council, where he oversaw various science areas and research funding programmes (including inflammation, cardiovascular and respiratory research), most recently leading the MRC-NIHR methodology research programme, and MRC's strategy and investments in experimental medicine.

He is now developing and implementing a new strategy and programme of research investments at CRUK which aims to accelerate progress towards earlier detection and prevention of cancer, through an integrated multidisciplinary approach, driven by improvements in health outcomes.

Dr Alexis Webb
CRUK

Biography

Alexis Webb is the Research Programme Manager in Early Detection at Cancer Research UK where she leads on several strategic initiatives in early detection and diagnosis research. Alexis has a PhD in neuroscience from Washington University in St Louis and, after finishing her postdoctoral research in Germany and the UK, joined Cancer Research UK in 2016. Alexis is passionate about building a multidisciplinary community of researchers who are interested in applying their skills to advance earlier detection of cancer and improve outcomes for patients. She is also an advocate for improving diversity in the STEM fields and supporting early career researchers.

Dr Gila Neta
National Cancer Institute

Biography

Gila is an epidemiologist and program director for Implementation Science in the Office of the Director in the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI). She serves as the NCI scientific lead for the funding announcements in Dissemination and Implementation Research in Health, and assists with research and training activities related to implementation science across the Division. She has a secondary appointment within the Epidemiology and Genomics Research Program.

Dr. Neta's programmatic and research interests within implementation science include training, portfolio analysis, the use of PRECIS criteria in evaluating pragmatic trials, shared decision making and cancer screening, economic evaluation, de-implementation, and the use of standardized measurement and reporting.

Professor Mihaela van der Schaar
University of Cambridge

Biography

Mihaela van der Schaar is the John Humphrey Plummer Professor of Machine Learning, Artificial Intelligence and Medicine at the University of Cambridge, a Fellow at The Alan Turing Institute in London, and a Chancellor's Professor at UCLA.

Mihaela was elected IEEE Fellow in 2009. She has received numerous awards, including the Oon Prize on Preventative Medicine from the University of Cambridge (2018), a National Science Foundation CAREER Award (2004), 3 IBM Faculty Awards, the IBM Exploratory Stream Analytics Innovation Award, the Philips Make a Difference Award and several best paper awards, including the IEEE Darlington Award.

In addition to leading the van der Schaar Lab, Mihaela is founder and director of the Cambridge Centre for AI in Medicine (CCAIM).

Abstract

While the ability of AI and machine learning to assist in diagnosing cancer is common knowledge, the discussion too often tends to revolve exclusively around one area: imaging. In this talk, Mihaela hopes to offer a broader perspective and explain how AI and machine learning can revolutionise the prevention and early diagnosis of cancer by supporting a range of diagnostic processes and empowering the human professionals behind those processes.

Drawing on examples developed by her own lab in close coordination with cancer experts, Mihaela will demonstrate how we can build and implement tools that can improve accuracy and efficiency of resource usage through effective diagnostic triaging, offer clinical decision support for screening, understand the progression of individual patient health and disease trajectories, produce dynamic personalised risk scores, and use information regarding morbidities and comorbidities to prevent or detect cancer.

HOLD THE DATES

Ca-PRI 2022 will be held (all being well)
on **Wednesday 6th – Friday 8th
April 2022**, in Oxford, UK.